Adjunctive Troriluzole for OCD

Recruiting at94 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Biohaven Pharmaceuticals, Inc.

Stay on Your Current Meds

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing a new medication called troriluzole to see if it helps people with OCD who aren't getting enough relief from their current treatments. Troriluzole is added to their existing medications and works by changing brain chemicals to reduce OCD symptoms. Troriluzole is related to riluzole, which has shown benefits in treating OCD when used alongside existing treatments.

Do I have to stop taking my current medications for the trial?

The trial does not specify if you need to stop your current medications. However, you must have an inadequate response to your current OCD medication, which should be a selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine, taken at a stable dose for at least 8 weeks before screening and 12 weeks at baseline.

What data supports the idea that Adjunctive Troriluzole for OCD is an effective drug?

The available research shows that riluzole, a drug similar to Troriluzole, has been tested in several studies for its effectiveness in treating OCD. These studies suggest that riluzole can help reduce symptoms in patients who do not respond well to standard treatments. For example, one study found that adding riluzole to ongoing treatment helped patients with severe OCD symptoms. However, the research primarily focuses on riluzole, and there is no specific data on Troriluzole's effectiveness for OCD in the provided information. ^{1 2 3 4 5}

What safety data is available for Troriluzole in treating OCD?

The provided research does not directly mention Troriluzole or its other names like BHV-4157, trigriluzole, or Dazluma. However, it discusses riluzole, a glutamate-modulating agent, which is related to Troriluzole. Riluzole has been studied in open-label and pilot randomized placebo-controlled trials for treatment-resistant OCD, suggesting potential benefits. Safety concerns specific to Troriluzole are not detailed in the provided abstracts, but riluzole's use in similar contexts may offer some indirect insights into its safety profile. ^{1 2 4 6 7}

Is the drug Troriluzole a promising treatment for OCD?

The provided research articles do not mention Troriluzole or its effects on OCD, so we cannot determine if it is a promising treatment based on this information. ^{8 9 10 11 12}

Research Team

Eligibility Criteria

This trial is for adults with Obsessive Compulsive Disorder (OCD) who haven't had enough improvement with standard treatments like certain antidepressants. They should be medically stable and able to complete the study, without a history of severe mental health disorders or brain injuries.

Inclusion Criteria

You have been diagnosed with obsessive-compulsive disorder (OCD) for at least one year, as confirmed by a mental health assessment.

An inadequate response to current Standard of Care medication defined as selective serotonin reuptake inhibitor (excluding fluvoxamine) or clomipramine treatment at an adequate and stable dose for at least 8 weeks prior to screening and at least 12 weeks at baseline (adequate dose defined by USPI labeling); an inadequate response too current standard of car base on the YBOCS score.

Determined by the investigator to be medically stable at baseline/ randomization as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing. Subjects must be physically able and expected to complete the trail as designed.

Exclusion Criteria

Subjects with a history of more than two (2) previous failed or inadequate treatment classes given for an adequate duration at an adequate dose as defined by the MGH-TRQ-OCD.

Are you b/t the ages of 18-65 years old?

Are you currently on a medication for your mental health?

Treatment Details

Interventions

• Placebo (Other)
• Troriluzole (Glutamate Modulator)

Trial Overview The trial is testing Troriluzole as an added treatment against a placebo in people with OCD. The goal is to see if it's effective and safe when used alongside current medications that aren't working well enough.

Participant Groups

Group I: Troriluzole Experimental Treatment 1 Intervention

Troriluzole- 2 100mg capsules once daily for the first two weeks. Troriluzole- 2 140mg capsules once daily from week two through week ten.

Group II: Placebo Placebo Group 1 Intervention

Placebo- 2 100mg capsules once daily for the first two weeks. Placebo- 2 140mg capsules once daily from week two through week ten.

Who Is Running the Clinical Trial?

Biohaven Pharmaceuticals, Inc.

Lead Sponsor

Trials

49

Recruited

30,100+

Findings from Research

In a pilot study involving 38 patients with obsessive-compulsive disorder (OCD) who were not responding well to standard serotonin reuptake inhibitors (SRIs), riluzole was found to be well tolerated with minimal side effects, suggesting it is a safe option for augmentation therapy.

While the overall improvement in OCD symptoms with riluzole did not reach statistical significance, there was a notable trend indicating potential benefits, particularly in outpatients, where more patients experienced at least a 25% improvement compared to those on placebo.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. Pittenger, C., Bloch, MH., Wasylink, S., et al.[2022]

In a 12-week open-label trial involving 6 children aged 8-16 with treatment-resistant OCD, 4 out of 6 subjects showed significant improvement in symptoms, with a reduction of over 46% on the Children's Yale-Brown Obsessive-Compulsive Scale.

Riluzole was well tolerated, with no adverse effects leading to discontinuation, and all participants chose to continue the medication after the trial, suggesting its potential as a safe alternative treatment for OCD.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Grant, P., Lougee, L., Hirschtritt, M., et al.[2022]

In an 8-week randomized trial with 50 patients, adding riluzole to fluvoxamine treatment significantly improved symptoms of moderate to severe obsessive-compulsive disorder, as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

The study found that patients receiving riluzole showed a greater reduction in both total Y-BOCS scores and the Compulsive subscale scores compared to those receiving fluvoxamine plus placebo, indicating that riluzole may enhance the efficacy of fluvoxamine in treating OCD.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. Emamzadehfard, S., Kamaloo, A., Paydary, K., et al.[2022]

In a study of 13 patients with treatment-resistant obsessive-compulsive disorder (OCD), the addition of riluzole significantly improved OCD symptoms, with 54% of participants showing over a 35% reduction in their Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores.

Riluzole was well tolerated and also led to significant improvements in depression and anxiety symptoms, suggesting it could be a beneficial augmentation therapy for patients who do not respond fully to standard treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Coric, V., Taskiran, S., Pittenger, C., et al.[2013]

In a study of 20 patients with treatment-resistant obsessive-compulsive disorder (OCD), adding amisulpiride to ongoing selective serotonin reuptake inhibitor (SRI) treatment resulted in a significant reduction in OCD symptoms, as measured by the Yale-Brown obsessive-compulsive scale (Y-BOCS).

Common side effects of amisulpiride included weight gain (70% of patients), mild sedation (65%), and asthenia (35%), indicating that while amisulpiride may be effective, it also carries notable risks that need to be considered.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Metin, O., Yazici, K., Tot, S., et al.[2022]

Obsessive-compulsive disorder (OCD) affects about 1 in 40 people in the U.S., and recent studies show that it can respond to drug treatments, particularly selective serotonin uptake inhibitors like clomipramine and fluoxetine.

Emerging research suggests that buspirone, which has anxiolytic and potential antidepressant effects, may provide direct benefits for OCD patients or enhance the effects of fluoxetine when used together.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Obsessive-compulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents. Murphy, DL., Pato, MT., Pigott, TA.[2013]

Teflutixol, a new thioxanthene derivative, was administered to 21 patients over 4 weeks, showing significant improvement in symptoms for patients with schizophrenia and obsessive-compulsive neurosis, as measured by the Brief Psychiatric Rating Scale (BPRS).

The treatment was well-tolerated, with most patients receiving a low daily dose of 1 mg or less, indicating that teflutixol may be an effective and safe option for managing these psychiatric conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Teflutixol (Lu 10-022): a new thioxanthene derivative with antipsychotic properties. A pilot study. Botte, L.[2012]

In a 4-week study involving 30 patients with endogenous depression, trazodone was found to be as effective as imipramine and significantly better than a placebo, showing antidepressant effects as early as 7 days into treatment.

Trazodone had fewer side effects, particularly anticholinergic effects, compared to imipramine, and its antidepressant effects were sustained for at least 5 months after the initial treatment phase.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A controlled study of trazodone, imipramine, and placebo in outpatients with endogenous depression. Mann, JJ., Georgotas, A., Newton, R., et al.[2019]

Compound 4, a trifluoromethanesulfonyloxy analogue of clozapine, shows higher affinity for dopamine D2 receptors compared to clozapine, indicating potential for enhanced efficacy in treating conditions like schizophrenia.

Unlike clozapine, compound 4 does not exhibit anticholinergic properties, which may lead to fewer side effects, making it a promising new neuroleptic candidate.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. Liao, Y., DeBoer, P., Meier, E., et al.[2013]

The new compound deschloroclozapine (DCZ) offers improved control over neuronal activity when used with designer receptors (DREADDs), showing higher potency and reduced off-target effects compared to the previously used clozapine-N-oxide (CNO).

DCZ allows for faster modulation of brain function in living animals, addressing the limitations of CNO's slow action and potential side effects, making it a more reliable tool for studying neuropsychiatric disorders.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals]. Nagai, Y.[2022]

New classes of triple reuptake inhibitors have been developed, showing high potency and selectivity for serotonin, norepinephrine, and dopamine transporters, which are important for treating mood disorders.

One promising compound, derivative 15, demonstrated good oral bioavailability and effective brain penetration in rats, making it a strong candidate for further development in treating depression or related conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. Micheli, F., Cavanni, P., Arban, R., et al.[2014]

References

1. United States pubmed.ncbi.nlm.nih.gov

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. [2022]

3. Australia pubmed.ncbi.nlm.nih.gov

Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. [2013]

5. England pubmed.ncbi.nlm.nih.gov

Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. [2022]

6. England pubmed.ncbi.nlm.nih.gov

A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Obsessive-compulsive disorder: treatment with serotonin-selective uptake inhibitors, azapirones, and other agents. [2013]

8. Belgium pubmed.ncbi.nlm.nih.gov

Teflutixol (Lu 10-022): a new thioxanthene derivative with antipsychotic properties. A pilot study. [2012]

9. United States pubmed.ncbi.nlm.nih.gov

A controlled study of trazodone, imipramine, and placebo in outpatients with endogenous depression. [2019]

10. United States pubmed.ncbi.nlm.nih.gov

Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic. [2013]

11. Japan pubmed.ncbi.nlm.nih.gov

[A novel ligand for chemogenetic receptors, Deschloroclozapine, enables rapid and selective modulation of neuronal activity and behavior in living animals]. [2022]

12. United States pubmed.ncbi.nlm.nih.gov

1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors. [2014]